findmyKOL

Saibal Kar, MD

Enriched profile

Director of Structural Heart Disease Interventions and Clinical Research, Los Robles Health System; Clinical Professor of Medicine, David Geffen School of Medicine at UCLA · Los Robles Health System

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Thousand Oaks, CA · West · United StatesSpecialtyInterventional CardiologyFocusCardiac Valve Diseases and Treatments+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Saibal Kar is Director of Structural Heart Disease Interventions and Clinical Research, Los Robles Health System; Clinical Professor of Medicine, David Geffen School of Medicine at UCLA at Los Robles Health System. OpenAlex indexes 415 publications with 31,870 citations (h-index 78); ClinicalTrials.gov lists 20 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Interventional Cardiology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 13 Oct 2026

Saibal Kar, MD, is Director of Structural Heart Disease Interventions and Clinical Research, Los Robles Health System. The public record shows 415 publications with 31,870 citations (h-index 78), centered on Cardiac Valve Diseases and Treatments, Cardiovascular Function and Risk Factors, Atrial Fibrillation Management and Outcomes. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 47 companies.

  • Most recent indexed publication: 2026 · Journal of the American Heart Association
  • Top research focus: Cardiac Valve Diseases and Treatments
  • 20 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 47 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Mitral Valve Insufficiency7 trialsAtrial Fibrillation5 trialsTricuspid Valve Insufficiency4 trialsStroke3 trialsHemorrhage2 trialsConstriction, Pathologic2 trialsCardiovascular Diseases1 trialHeart Defects, Congenital1 trialCongenital Abnormalities1 trialVascular Diseases1 trialHeart Septal Defects, Atrial1 trialCardiovascular Abnormalities1 trialHeart Septal Defects1 trialHeart Valve Diseases1 trialAortic Valve Insufficiency1 trialAortic Valve Stenosis1 trialMitral Valve Stenosis1 trialCoronary Artery Disease / ACS1 trialCoronary Artery Disease1 trialST Elevation Myocardial Infarction1 trialEmbolism1 trial

Research focus

OpenAlex concept fingerprint
Cardiac Valve Diseases and TreatmentsCardiovascular Function and Risk FactorsAtrial Fibrillation Management and OutcomesCardiac pacing and defibrillation studiesCardiac Arrhythmias and Treatments

Drugs & molecules

across trials, industry payments and publications
Repathageneric · EvolocumabClinical trials—Industry payments11Publications—Entrestogeneric · Sacubitril / valsartanClinical trials—Industry payments4Publications—Vyndaqelgeneric · TafamidisClinical trials—Industry payments4Publications—Leqviogeneric · InclisiranClinical trials—Industry payments3Publications—Amvuttrageneric · VutrisiranClinical trials—Industry payments2Publications—Arcalystgeneric · RilonaceptClinical trials—Industry payments2Publications—Rybelsusgeneric · SemaglutideClinical trials—Industry payments2Publications—Verquvogeneric · VericiguatClinical trials—Industry payments2Publications—Furoscixgeneric · FurosemideClinical trials—Industry payments1Publications—Tyvasogeneric · TreprostinilClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Boston Scientific CorporationClinical trials4Industry payments249Biosense Webster, Inc.Clinical trials1Industry payments10Abbott LaboratoriesClinical trials—Industry payments440Medtronic, Inc.Clinical trials—Industry payments394AbiomedClinical trials—Industry payments30Edwards Lifesciences CorporationClinical trials—Industry payments28W. L. Gore & Associates, Inc.Clinical trials—Industry payments19Amgen Inc.Clinical trials—Industry payments12Heartflow, Inc.Clinical trials—Industry payments11Inari Medical, Inc.Clinical trials—Industry payments10Biotronik Inc.Clinical trials—Industry payments9Shockwave Medical, IncClinical trials—Industry payments7Siemens Medical Solutions USA, Inc.Clinical trials—Industry payments7ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Clinical trials—Industry payments6iRhythm Technologies, Inc.Clinical trials—Industry payments5Novartis Pharmaceuticals CorporationClinical trials—Industry payments5Penumbra, Inc.Clinical trials—Industry payments5Pfizer Inc.Clinical trials—Industry payments4Abbott Medical DevicesClinical trials3Industry payments—Atricure, Inc.Clinical trials—Industry payments3Cardiva Medical, Inc.Clinical trials—Industry payments3Ge HealthcareClinical trials—Industry payments3Medtronic CardiovascularClinical trials3Industry payments—Philips Electronics North America CorporationClinical trials—Industry payments3Alnylam Pharmaceuticals Inc.Clinical trials—Industry payments2AngioDynamics, Inc.Clinical trials—Industry payments2Cordis Us Corp.Clinical trials—Industry payments2Kiniksa Pharmaceuticals International, plcClinical trials—Industry payments24C Medical Technologies, Inc.Clinical trials1Industry payments—Asahi Intecc USA, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
415publications

Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.

31,870citations

Total citations across indexed works.

78h-index

Hirsch index (OpenAlex). i10-index 195.

Clinical & industry

trials, payments and federal funding
20clinical trials

Investigator role on registered studies.

View trials ↓
47companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Oct 2026

47 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    55.5%
    Angiotensin receptor-neprilysin inhibitor (ARNI)20.4%
    Entresto100%
    Part D<11 patients
    Beta blocker19.7%
    Carvedilol59%Metoprolol Succinate41%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    30.7%
    SGLT2 inhibitor22.6%
    Farxiga100%
    Part D≥13 patients
    Potassium supplement8%
    Potassium Chloride100%
    Part D<11 patients
  • Blood & clotting

    13.9%
    P2Y12 inhibitor13.9%
    Clopidogrel100%
    Part D≥11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 13 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 13 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Michael J. Mack73Raj Makkar64William T. Abraham64Gregg W. Stone63Robert J. Siegel60JoAnn Lindenfeld59Brian Whisenant59D. Scott Lim58Paul Grayburn52Ted Feldman50Federico M. Asch48Scott Lim38Neil J. Weissman38Michael Rinaldi37Moody Makar36Asma Hussaini36Takahiro Shiota36David R. Holmes36Samir Kapadia36Alfredo Trento32Mamoo Nakamura32Björn Redfors28Vivek Y. Reddy28Shephal K. Doshi26Matthew J. Price26Jacob M. Mishell24Richard W. Smalling23William W. O’Neill22Elyse Foster22Robert Kipperman21David J. Cohen21Azeem Latib20Ralph Stephan von Bardeleben20Neil Fam20Francesco Maisano19Takashi Matsumoto19Shunsuke Kubo19Neal Eigler18Rebecca T. Hahn18Florian Rader18

Online presence

Updated 13 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    scai.org/about-us/scai-staff-listing/saibal-kar-md-fscai

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scai.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
  • FACC

    Fellow of the American College of Cardiology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cacvi.org ↗
  • FSCAI

    Fellow of the Society for Cardiovascular Angiography and Interventions

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scai.org ↗

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.